The sales decline was largely due to a slowdown in productivity related to the recent launch of the company's global enterprise resource planning system in Western Europe.
The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents.
Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The UCSF-based Blood Systems Research Institute will conduct research using RainDance's digital PCR platforms as part of a new $20 million amfAR Institute for HIV Cure Research.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The company filed to go public in March with plans to offer up to $60 million of its stock.
The company has established a streamlined workflow that customizes and automates key steps of the sample prep process.
The solutions will combine RainDance's digital droplet technology and single-molecule barcoding technology with PacBio's proprietary long-range DNA amplification technology.
China is embracing preimplantation genetic diagnosis, Nature News reports.
In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.